Tobacco Use Disorder — Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures
Citation(s)
Angrist A, Imbens G, Rubin D Identification of Causal Effects Using Instrumental Variables. Journal of the American Statistical Association 1996;91:444-55.
Baker F, Johnson MW, Bickel WK Delay discounting in current and never-before cigarette smokers: similarities and differences across commodity, sign, and magnitude. J Abnorm Psychol. 2003 Aug;112(3):382-92.
Bickel WK, Odum AL, Madden GJ Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology (Berl). 1999 Oct;146(4):447-54.
Bradley EH, Curry LA, Devers KJ Qualitative data analysis for health services research: developing taxonomy, themes, and theory. Health Serv Res. 2007 Aug;42(4):1758-72.
Burns DM, Shanks T, Major J, Gower KB, Shopland D Restrictions on Smoking in the Workplace: Smoking and Tobacco Control Monograph No. 12. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, National Cancer Institute; 2002.
Centers for Disease Control and Prevention (CDC) State-specific smoking-attributable mortality and years of potential life lost--United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2009 Jan 23;58(2):29-33. Erratum in: MMWR Morb Mortal Wkly Rep. 2009 Feb 6;58(4):91.
Chapman GB Time discounting of health outcomes In: Loewenstein G, Read D, Baumeister R, eds. Time and decision: Economic and psychological perspectives on intertemporal choice. New York, NY: Russell Sage Foundation; 2003:395-417.
Charmaz K Constructing grounded theory: a practical guide through qualitative analysis. Thousand Oaks, CA: Sage Publications; 2006.
Connolly T, Butler DU Regret in Economic and Psychological Theories of Choice. Journal of Behavioral Decision Making 2006;19(2):148-58.
Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997 Dec 3;278(21):1759-66.
Dragalin V Adaptive designs: Terminology and classification. Drug Information Journal 2006;40(4):425-35.
Efron B International Symposium on Hodgkin's Disease. Session 6. Survival data and prognosis. Invited discussion: Forcing a sequential experiment to be balanced. Natl Cancer Inst Monogr. 1973 May;36:571-2.
Giacomini MK, Cook DJ Users' guides to the medical literature: XXIII. Qualitative research in health care A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 2000 Jul 19;284(3):357-62.
Giuffrida A, Torgerson DJ Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ. 1997 Sep 20;315(7110):703-7. Review.
Greenland S, Schwartzbaum JA, Finkle WD Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol. 2000 Mar 1;151(5):531-9. Review.
Guo WS, Ratcliffe SJ, Ten Have TT A random pattern-mixture model for longitudinal data with dropouts. Journal of the American Statistical Association 2004;99(468):929-37.
Halpern SD, Madison KM, Volpp KG Patients as mercenaries?: the ethics of using financial incentives in the war on unhealthy behaviors. Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):514-6. doi: 10.1161/CIRCOUTCOMES.109.871855.
Halpern SD, Raz A, Kohn R, Rey M, Asch DA, Reese P Regulated payments for living kidney donation: an empirical assessment of the ethical concerns. Ann Intern Med. 2010 Mar 16;152(6):358-65. doi: 10.7326/0003-4819-152-6-201003160-00005.
Hatsukami DK, Stead LF, Gupta PC Tobacco addiction. Lancet. 2008 Jun 14;371(9629):2027-38. doi: 10.1016/S0140-6736(08)60871-5. Review.
Higgins ST, Bickel WK, Hughes JR Influence of an alternative reinforcer on human cocaine self-administration. Life Sci. 1994;55(3):179-87.
Higgins ST, Heil SH, Dantona R, Donham R, Matthews M, Badger GJ Effects of varying the monetary value of voucher-based incentives on abstinence achieved during and following treatment among cocaine-dependent outpatients. Addiction. 2007 Feb;102(2):271-81.
Hoelzl E, Loewenstein G Wearing out your shoes to prevent someone else from stepping into them: Anticipated regret and social takeover in sequential decisions. Organizational Behavior and Human Decision Processes 2005;98:15-27.
Hosmer DW, Lemeshow S Model building strategies and methods for logistic regression. In: Hosmer DW, Lemeshow S, eds. Applied Logistic Regression, 2nd Edition. New York: John Wiley & Sons; 2000.
Hu FF, Zhang LX, He XM Efficient Randomized-Adaptive Designs. Annals of Statistics 2009;37(5A):2543-60.
Johnson MW, Bickel WK, Baker F Moderate drug use and delay discounting: a comparison of heavy, light, and never smokers. Exp Clin Psychopharmacol. 2007 Apr;15(2):187-94.
Kahneman D, Tversky A Prospect theory: An analysis of decision under risk. Econometrica 1979;47:263-91.
Mokdad AH, Marks JS, Stroup DF, Gerberding JL Actual causes of death in the United States, 2000. JAMA. 2004 Mar 10;291(10):1238-45. Review. Erratum in: JAMA. 2005 Jan 19;293(3):298. JAMA. 2005 Jan 19;293(3):293-4.
Newhouse JP, McClellan M Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17-34. Review.
Petry NM, Martin B, Cooney JL, Kranzler HR Give them prizes, and they will come: contingency management for treatment of alcohol dependence. J Consult Clin Psychol. 2000 Apr;68(2):250-7.
Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975 Mar;31(1):103-15.
Schotter A, Weigelt K Behavioral Consequences of Corporate Incentives and Long-Term Bonuses - an Experimental-Study. Manage Sci 1992;38(9):1280-98.
Silverman K, Chutuape MA, Bigelow GE, Stitzer ML Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl). 1999 Sep;146(2):128-38.
Small DS, Ten Have TR, Joffe MM, Cheng J Random effects logistic models for analysing efficacy of a longitudinal randomized treatment with non-adherence. Stat Med. 2006 Jun 30;25(12):1981-2007.
Strauss AL, Corbin J Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. Thousand Oaks, CA: Sage; 1998.
Ten Have TR, Elliott MR, Joffe M, Zanutto E, Datto C Causal models for randomized physician encouragement trials in treating primary care depression. Journal of the American Statistical Association 2004;99(465):16-25.
Ten Have TR, Joffe M, Cary M Causal logistic models for non-compliance under randomized treatment with univariate binary response. Stat Med. 2003 Apr 30;22(8):1255-83.
Thaler RH Mental Accounting and Consumer Choice. Marketing Science 1985;4:199-214.
Thaler RH Some empirical evidence on time inconsistency. Review of Economic Studies 1981;23:165-80.
U S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. Washington, DC: U.S. Department of Health and Human Services; 2000.
Volpp KG, Pauly MV, Loewenstein G, Bangsberg D P4P4P: an agenda for research on pay-for-performance for patients. Health Aff (Millwood). 2009 Jan-Feb;28(1):206-14. doi: 10.1377/hlthaff.28.1.206.
Westman EC, Behm FM, Simel DL, Rose JE Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med. 1997 Feb 10;157(3):335-40.
Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
